BioSpace News Archive

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that the first subject treated with the optimized MB-106 (CD20-targeted, autologous CAR T cell therapy) manufacturing process, developed in collaboration between Mustang and Fred Hutchinson Cancer Research Center (“Fred Hutch”), has achieved a complete response (CR) at the lowest starting dose in an ongoing Phase 1/2 clinical trial.

Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that it has expanded its clinical development program for REN001, into glycogen storage disease type V (GSD V), also known as McArdle disease.

Korea Centers for Disease Control & Prevention notified Seegene Inc. (096530.KQ) that Korea Ministry of Food and Drug Safety (MFDS; Former KFDA) approved its novel coronavirus (COIVD-19) Real-time PCR assay for the Emergency Use, following the recent CE-IVD Mark

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release fourth quarter and fiscal year 2019 financial and operating results, and certain guidance for the first quarter and full year 2020, prior to market open on Tuesday, March 3, 2020.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the sixth annual STRIVE grant awards program for Duchenne muscular dystrophy.

Caregility, a clinical collaboration and communications company focused on providing secure, reliable two-way audio and video communications for any device and clinical workflow, in both inpatient and outpatient settings, announces IEC 60601-1 certification of its UHE™ telehealth platform.

Lee Health announced that it will begin offering clinic-based specialty pharmacy services in February.

Stryker, one of the world’s leading medical technology companies, announced it has been named one of Fortune’s 2020 100 Best Companies to Work For in its annual survey and evaluation of top-rated workplaces in the United States for a 10th consecutive year.

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis

Baxter International Inc., a leading global medical products company, announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per share of common stock.